Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxi-city? - Spaepen, K; Stroobants, S; Dupont, P (Br J Haematol, 2001)